Opinion|Videos|April 11, 2025
Utilizing Patient Factors to Guide Treatment Selection in Atopic Dermatitis
Experts discuss situations where an oral JAK inhibitor might be prescribed initially over a biologic for moderate to severe atopic dermatitis (AD), noting advantages such as oral administration, quicker onset of action, and convenience, which may make it a preferred option for some patients.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are some circumstances where you would prescribe an oral JAK inhibitor for moderate to severe AD initially over a biologic?
- What advantages might a JAK inhibitor have over a biologic?
Advertisement
Related to this article
Lp(a)HORIZON and ZEUS hit their biomarker targets but not MACE. Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, unpack both at AHA 2026.
Emma Guttman-Yassky, MD, discusses biomarker data showing rezpegaldesleukin's regulatory T-cell mechanism separates from placebo early.
Risankizumab improved skin clearance, itch, and quality of life through 52 weeks in pediatric psoriasis in the phase 3 OptIMMize-1 study.
In 3-year BE HEARD data, close to half of bimekizumab-treated HS patients reported no quality-of-life impact, regardless of baseline draining tunnel count.
Autumn Burnette, MD, hosts a new monthly allergy and immunology podcast from HCPLive, opening with an episode on hereditary angioedema.
Martina Porter, MD, of Beth Israel Deaconess Medical Center discusses unmet needs in HS and where oral povorcitinib fits among emerging options.
Juanita Mora, MD, of Chicago Allergy Center discusses strategies from boosters and antiviral prophylaxis to specialist counseling.
Stay updated with the latest healthcare breakthroughs, including 96-week durability data for GSK’s bepirovirsen in hepatitis B, and more.
Advertisement
Advertisement
Trending on HCPLive
1
Zabopegdutide Improves Fibrosis, MASH Resolution at 48 Weeks
2
Asundexian Receives FDA Approval for Secondary Stroke Prevention
3
RNA Editing With WVE-006 Restores Functional AAT, Cuts Z-AAT in AATD
4
Efinopegdutide Improves MASH Resolution, Fibrosis in Phase 2b Trial
5